Brightgene Bio-medical

BrightGene Bio-Medical’s GLP-1/GIP dual receptor agonist **BGM0504** achieves significant cardiometabolic improvements in Phase III trials. The treatment delivers **19.3% average weight loss**, reduces waist circumference by **16.5 cm**, and lowers blood pressure by **22.9/12.9 mmHg**. It also cuts uric acid levels by **70.7 μmol/L** and triglycerides by **33.6%** in participants with overweight or obesity. The topline results highlight its potential for broad metabolic regulation beyond glucose control.

May 2026The Manila TimesNews article

BrightGene reports early-stage results showing its oral dual agonist achieves up to 8% weight loss in participants after 8 weeks. The data highlights the company’s progress in developing an oral treatment for obesity. The findings come from a subset of early clinical trial results.

Mar 2026Fierce BiotechNews article

BrightGene reports that its oral drug candidate **BGM0504** demonstrates **general tolerability** in Phase 1 trials for obesity treatment across **China and the United States**. The topline results suggest early safety validation for the compound in human testing. BrightGene develops novel therapeutics targeting metabolic disorders.

Mar 2026PR NewswireNews article

BrightGene Bio-Medical Technology partners with China Resources Sanjiu Medical to develop, register, manufacture, and commercialize **BGM0504 Injection** in mainland China. The agreement grants CR Sanjiu exclusive rights for commercialization and collaborative development, excluding Hong Kong, Macau, and Taiwan. Both companies will jointly advance the drug’s regulatory approval and market introduction.

Aug 2025Insight, China's Pharmaceutical IndustryNews article